Multi-year partnership agreement features
in-arena advertising, promotions, and community services
Partnership includes donation of Quidel’s
QuickVue® At-Home OTC COVID-19 Tests to Chicago Blackhawks
Foundation community partners
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider
of rapid diagnostic testing solutions, cellular-based virology
assays and molecular diagnostic systems, has executed a multi-year
partnership agreement with the Chicago Blackhawks to sponsor team
promotions and community services. In the first year of the
partnership agreement, the Blackhawks will work with Quidel to
provide QuickVue At-Home OTC COVID-19 Tests free-of-charge to
multiple Chicago Blackhawks Foundation community partners to help
support local youth and their program staff to continue to learn
and play with greater peace of mind.
“Quidel’s partnership with the Chicago Blackhawks grew out of
our commitment to expand equitable access to healthcare and our
shared dedication to service, especially in this time of great
need,” said Douglas Bryant, President and CEO of Quidel. “We look
forward to working with the Blackhawks, Fifth Third Arena, and the
Chicago Blackhawks Foundation on initiatives that address current
community health needs in ways that can create a positive impact.
We believe our QuickVue At-Home rapid antigen tests will be
particularly effective in this regard.”
Recipients of the first Quidel donation include SOS Villages,
Millennium Enterprises, Marillac St. Vincent Family Services,
Austin Childcare Providers Network, The Bloc Chicago, and Cocina
Fusion.
“We are grateful to Quidel for their donation of QuickVue
At-Home OTC COVID-19 Tests to a number of our Chicago Blackhawks
Foundation partners, who each serve our neighboring West Side
community in a unique way,” said Sara Guderyahn, Blackhawks Vice
President of Community Partnerships & Executive Director of the
Chicago Blackhawks Foundation. “As our community continues to work
to keep Chicago safe from COVID-19, Quidel’s donation will help
these organizations quickly identify potential outbreaks and
support efforts to keep everything from afterschool programming to
small businesses running.”
The QuickVue At-Home OTC COVID-19 Test allows individuals to
easily perform the test themselves without a doctor’s prescription
and get results in 10 minutes from nasal swab samples. The QuickVue
At-Home OTC COVID-19 Test shows excellent performance, with
positive results agreeing with PCR 83.5% of the time, and negative
results agreeing 99.2% of the time, delivering confidence to
individuals running the test and helping to prevent asymptomatic
virus spread.
In addition to the community health initiative that is the
bedrock of Quidel’s partnership with the Blackhawks, Quidel’s
sponsorship agreement with the Blackhawks includes in-arena and
practice facility marketing assets as well as sponsorship of an
“Instant Analysis” feature during games.
“Our mission has been to democratize access to affordable and
highly accurate COVID-19 testing so that people can take charge of
their own health and protect others,” Mr. Bryant noted. “The rapid
testing and health education we are doing in partnership with the
Chicago Blackhawks Foundation can provide the broader community a
trusted brand to turn to for critical information they need to
return some normalcy to their lives,” he concluded.
The QuickVue At-Home OTC COVID-19 Test is only for use under the
Food and Drug Administration’s Emergency Use Authorization. The
QuickVue At-Home OTC COVID-19 Test has not been FDA-cleared or
approved. The test has been authorized only for the detection of
proteins from SARS-CoV-2, not for any other viruses or pathogens,
and is only authorized for the duration of the declaration that
circumstances exist justifying the authorization of emergency use
of in vitro diagnostic tests for detection and/or diagnosis of
COVID-19 under Section 564(b)(1) of the Federal Food, Drug and
Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is
terminated or authorization is revoked sooner.
About the Chicago Blackhawks Foundation
As the Chicago Blackhawks’ official charitable arm, the Chicago
Blackhawks Foundation works to create a healthier, smarter, more
secure world for children and families across Chicagoland. By
providing access to programming and resources that make a positive
impact, the organization strives to invest in Chicagoland’s youth,
support local families in need and honor the sacrifices of others
in addition to growing the great game of hockey. For more
information, please visit Blackhawks.com/Foundation.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of
diagnostic solutions at the point of care, delivering a continuum
of rapid testing technologies that further improve the quality of
health care throughout the globe. An innovator for over 40 years in
the medical device industry, Quidel pioneered the first FDA-cleared
point-of-care test for influenza in 1999 and was the first to
market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted
brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue, Quidel’s
comprehensive product portfolio includes tests for a wide range of
infectious diseases, cardiac and autoimmune biomarkers, as well as
a host of products to detect COVID-19. With products made in
America, Quidel’s mission is to provide patients with immediate and
frequent access to highly accurate, affordable testing for the good
of our families, our communities and the world. For more
information about Quidel, visit quidel.com.
View our story told by our people at www.quidel.com/ourstory
Forward-Looking Statements
This press release contains forward-looking statements that
involve material risks, assumptions, and uncertainties.
Forward-looking statements typically contain terms such as “may,”
“will,” “should,” “might,” “expect,” “anticipate,” “estimate,”
“plan,” “intend,” “goal,” “project,” “strategy,” “future,” and
similar words. Various factors could cause our actual results and
performance to differ materially from the forward-looking
statements. Factors that could contribute to such differences
include: the evolution of the COVID-19 pandemic and it’s impact;
competition; our development of new technologies, products, and
markets; our reliance on sales of our COVID-19 and influenza
diagnostic tests; our reliance on a limited number of key
distributors; acceptance of our products among physicians,
healthcare providers, or other customers; the impact of third-party
reimbursement policies; our ability to meet demand for our
products; interruptions in our supply of raw materials and other
product and production components; costs and disruptions from
failures in our information technology and storage systems;
international risks, including compliance with product registration
requirements and legal requirements, tariffs, currency exchange
fluctuations, reduced protection of intellectual property rights,
and taxes; worldwide economic, political, and social uncertainty;
our development, acquisition, and protection of proprietary
technology rights; intellectual property risks and third-party
claims of infringement, loss of our Emergency Use Authorization
from the U.S. Food and Drug Administration for our COVID-19
products; failures or delays in receiving regulatory approvals,
clearances, or authorizations, the loss of previously received
approvals, or other adverse actions by regulatory authorities;
performance, timing, funding and compliance risks relating to
government contracts; product defects; compliance with government
regulations relating to the handling, storage, and disposal of
hazardous substances; our ability to identify and successfully
acquire and integrate potential acquisition targets; our need for
additional funds to finance our capital or operating needs; and
other risks described in our periodic reports and registration
statements filed with the Securities and Exchange Commission.
Except as required by law, we undertake no obligation to update
these forward-looking statements for revisions or changes after the
date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211215005934/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931
Media and Investors Contact: Quidel Corporation Ruben Argueta
(858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2023 to Jul 2024